This program is supported by an independent educational grant from MSD. This online education program is designed solely for healthcare professionals in the USA. The content is not available for HCPs in any other country.

Join PAH experts Dr. Sudarshan Rajagopal and Dr. Kelly Chin for this accredited, interactive 60-minute teaching session. Through real-world cases, faculty will expose common misconceptions that lead to suboptimal outcomes and demonstrate how guideline-directed, risk-based decision-making can meaningfully improve patient care.

Accreditation: 1 AMA PRA Category 1 Credit™

Session Highlights

The live virtual webinar will feature four interactive, case-based discussions, each structured around a prevalent myth in PAH management. The real-world cases highlight the underlying misconception driving suboptimal care, and guide participants through the evidence-based reasoning needed to rethink PAH care.

Myth 1: The Traditional Stepwise Approach Is Still Sufficient

Many patients continue to start on long-term monotherapy, reflecting older stepwise habits. Evidence and modern guidelines show this approach is outdated—early combination therapy and treat-to-target strategies improve outcomes.

Myth 2: Monotherapy Is Usually Enough

Initial improvement often does not equate to long-term stability. Most patients will not reach or maintain low-risk status on monotherapy alone. Dual or triple therapy—upfront or sequential—is frequently needed to achieve treatment goals.

Myth 3: A Patient Who Feels Better Is Stable

Symptom improvement can mask progression. Objective risk assessment tools (NT-proBNP, 6MWD, RV function, imaging) are essential for determining true stability and guiding therapy adjustment.

Myth 4: Escalation Can Wait Until Patients Worsen

Waiting for overt deterioration permits disease advancement. Guidelines increasingly emphasize proactive treatment intensification, allowing patients to reach and maintain low-risk status and improve long-term outcomes.

Who Should Attend?

This program is for U.S. healthcare professionals involved in PAH care, including:

Pulmonologists
Cardiologists
Internal Medicine Physicians
Nurse Practitioners & Physician Assistants
Pharmacists
Nurses and other HCPs involved in the management of PAH

Faculty

Sudarshan Rajagopal, M.D., Ph.D.

Cardiologist and physician–scientist at Duke Health with expertise in pulmonary arterial hypertension and advanced heart failure. He combines clinical care with translational research focused on pulmonary vascular biology, GPCR signaling, and novel therapeutic strategies. Dr. Rajagopal plays a leading role in multidisciplinary PAH programs and is recognized for advancing mechanism-based, patient-centered approaches to cardiovascular and pulmonary vascular disease.

Kelly Chin, M.D.

Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center and Professor of Internal Medicine. Dr. Chin is a nationally recognized authority in PAH clinical care and clinical trials, with extensive experience advancing guideline-based treatment approaches, risk assessment strategies, and therapeutic optimization.

Continuing Education Information

Commercial support: This activity received monetary support through an independent education grant from MSD.

This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.

Disclosures

Sudarshan Rajagopal, MD, PhD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Consultant for Altavant, GossamerBio, Insmed, Janssen, Liquidia, Merck, Pahr Therapeutics, United Therapeutics. Research Support from American Heart Association, Janssen, Merck, NIH, United Therapeutics. These disclosures are provided in accordance with ACCME standards to ensure transparency and uphold the integrity of continuing education. Dr. Rajagopal does not intend to reference any unlabeled or unapproved uses of products during the presentation.

Kelly Chin, MD has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board/Steering or Adjudication Committee for Gossamer Bio, Inhibikase, Janssen, Merck, United Therapeutics. Research Support (for institution) from Gossamer Bio, Janssen, Merck, Novartis, Pulmovant and United Therapeutics. These disclosures are provided in accordance with ACCME standards to ensure transparency and uphold the integrity of continuing education. Dr. Chin does not intend to reference any unlabeled or unapproved uses of products during the presentation.

AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.

Mitigation of Relevant Financial Relationships

AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.

Activity Accreditation for Health Professions

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

CME Inquiries

For all CME policy-related inquiries, please contact us at ce@affinityced.com.

Participation Costs

There is no cost to participate in this program.

This continuing education activity is active starting February 5th 2026 and will expire on February 5th 2026.

Estimated time to complete this activity: 60 minutes.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.

Learning objectives

Upon completion of this activity, participants should be better able to:

1. Describe the major pathophysiological pathways underlying PAH and how they inform therapeutic targets.

2. Apply current international guideline recommendations to ensure evidence-based use of approved PAH therapies.

3. Differentiate between monotherapy, dual therapy, and triple therapy approaches, highlighting their appropriate use in clinical practice.

4. Determine when and how to escalate therapy in patients with PAH, using risk stratification and clinical response to guide treatment intensification.

5. Develop personalized treatment plans that integrate guideline-directed therapy, pathway-based rationale, and patient-specific factors to optimize outcomes.

View all